JUNE | 2012
MJFF LAUNCHES FIRST SMART- MATCH TOOL FOR PARKINSON ’ S STUDIES
Slow recruitment of volunteers for clinical trials is a major hurdle to Parkinson ’ s research progress . MJFF launches a smart-match tool to connect volunteers with clinical trials based on location and medical history . The tool centralizes information about research participation in one user-friendly website , and enables two-way messaging between clinical trial teams and potential volunteers , while preserving volunteers ’ anonymity . Tens of thousands of individuals sign up to join a standing army of research volunteers for Parkinson ’ s studies .
ALPHA-SYNUCLEIN TREATMENT ENTERS FIRST CLINICAL TRIALS
Scientists hypothesize that a therapy targeting alpha-synuclein — the protein that clumps in the cells of people with Parkinson ’ s — may be our best target for a drug that would help the broad disease population . The Foundation ’ s de-risking strategy drives the advancement of alphasynuclein therapeutics to development as biotechs AFFiRiS and ReMYnd announce that their synuclein programs are entering the first human trials . This leap paves the way for 12 other alpha-synuclein therapies to enter clinical testing by 2020 .
APRIL | 2012 11